111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
卡格列净作为结节性硬化症复合体潜在的临床前治疗药物：通过细胞周期停滞和线粒体功能障碍抑制 Tsc2−/− 细胞增殖
Authors Ye J, Liu B , Wu J, Gao H, Wei Q, Su K, Zheng K, Dai X, Xu T, Wang Y, Liu S, Peng X , Gou L, Zhao Y, Xue B
Received 31 March 2025
Accepted for publication 24 November 2025
Published 4 December 2025 Volume 2025:19 Pages 10719—10733
DOI https://doi.org/10.2147/DDDT.S525749
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Muzammal Hussain
Juan Ye,1,2,* Boyuan Liu,3,* Jing Wu,4,* Hongliang Gao,5 Qingyun Wei,2 Kelei Su,2 Kai Zheng,6 Xuening Dai,3 Tao Xu,3 Yuqi Wang,3 Shuangchi Liu,7 Xing Peng,3 Liming Gou,4 Yinjuan Zhao,8,* Bin Xue1,4,7,9,10
1Medical School, Nanjing University Nanjing, Jiangsu, 210023, People’s Republic of China; 2Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210028, People’s Republic of China; 3Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People’s Republic of China; 4Translational Medicine Research Center, Children’s Hospital of Nanjing Medical University, Nanjing, 210000, People’s Republic of China; 5Department of Pathophysiology, Wannan Medical college, Wuhu, 241002,People’s Republic of China; 6Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, 210029, People’s Republic of China; 7Department of General Surgery, the Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, 213003, People’s Republic of China; 8Collaborative Innovation Center of Sustainable Forestry in Southern China, College of Forestry, Nanjing Forestry University, Nanjing, 210037, People’s Republic of China; 9NHC Key Laboratory of Antibody Technique, Nanjing Medical University, Nanjing, People’s Republic of China; 10Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211166, People’s Republic of China
*These authors contributed equally to this work: Juan Ye, Boyuan Liu, Jing Wu
Correspondence: Bin Xue, Email xuebin@njmu.edu.cn Yinjuan Zhao, Email zhaoyinjuan@njfu.edu.cn
Purpose: Canagliflozin (Ca), a sodium-glucose cotransporter 2 (SGLT2) inhibitor traditionally used for type 2 diabetes, has shown potential in the treatment of lymphangiomatosis (the pulmonary lesion phenotype of TSC). However, its effects on Tsc2−/− cells, a key feature of tuberous sclerosis complex (TSC), have not been previously explored. This preclinical study aimed to investigate Ca’s inhibitory mechanisms on Tsc2−/− cell proliferation and its therapeutic potential in TSC-related lesions.
Methods: The effects of Ca on Tsc2−/− cells were evaluated using in vitro cellular assays, including proliferation, cell cycle, and mitochondrial function analyses, as well as proteomics. In vivo, a mouse xenograft model was employed to assess tumor growth inhibition and safety profile. Comparative studies with other SGLT2 inhibitors were conducted to identify compound-specific mechanisms.
Results: Ca significantly inhibited Tsc2−/− cell proliferation in a dose-dependent manner, inducing G1 phase cell cycle arrest and impairing mitochondrial function, as evidenced by reduced membrane potential and ATP production. Proteomic analysis revealed mitochondrial protein alterations, and Ca-induced ROS accumulation promoted apoptosis. In vivo, Ca (100 mg/kg/day) effectively suppressed tumor growth without significant adverse effects. Notably, Ca’s effects were unique compared to other SGLT2 inhibitors, indicating mechanisms independent of SGLT2 inhibition.
Conclusion: Ca inhibits Tsc2−/− cell proliferation through dual mechanisms of cell cycle arrest and mitochondrial impairment, demonstrating significant therapeutic potential for TSC-related lesions. These findings highlight Ca as a promising alternative to current mTOR inhibitors, warranting further investigation into its molecular targets and clinical applications.
Keywords: canagliflozin, rare diseases, mitochondrial impairment, Tsc2 gene
1Medical School, Nanjing University Nanjing, Jiangsu, 210023, People’s Republic of China; 2Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210028, People’s Republic of China; 3Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People’s Republic of China; 4Translational Medicine Research Center, Children’s Hospital of Nanjing Medical University, Nanjing, 210000, People’s Republic of China; 5Department of Pathophysiology, Wannan Medical college, Wuhu, 241002,People’s Republic of China; 6Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, 210029, People’s Republic of China; 7Department of General Surgery, the Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, 213003, People’s Republic of China; 8Collaborative Innovation Center of Sustainable Forestry in Southern China, College of Forestry, Nanjing Forestry University, Nanjing, 210037, People’s Republic of China; 9NHC Key Laboratory of Antibody Technique, Nanjing Medical University, Nanjing, People’s Republic of China; 10Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211166, People’s Republic of China
*These authors contributed equally to this work: Juan Ye, Boyuan Liu, Jing Wu
Correspondence: Bin Xue, Email xuebin@njmu.edu.cn Yinjuan Zhao, Email zhaoyinjuan@njfu.edu.cn
Purpose: Canagliflozin (Ca), a sodium-glucose cotransporter 2 (SGLT2) inhibitor traditionally used for type 2 diabetes, has shown potential in the treatment of lymphangiomatosis (the pulmonary lesion phenotype of TSC). However, its effects on Tsc2−/− cells, a key feature of tuberous sclerosis complex (TSC), have not been previously explored. This preclinical study aimed to investigate Ca’s inhibitory mechanisms on Tsc2−/− cell proliferation and its therapeutic potential in TSC-related lesions.
Methods: The effects of Ca on Tsc2−/− cells were evaluated using in vitro cellular assays, including proliferation, cell cycle, and mitochondrial function analyses, as well as proteomics. In vivo, a mouse xenograft model was employed to assess tumor growth inhibition and safety profile. Comparative studies with other SGLT2 inhibitors were conducted to identify compound-specific mechanisms.
Results: Ca significantly inhibited Tsc2−/− cell proliferation in a dose-dependent manner, inducing G1 phase cell cycle arrest and impairing mitochondrial function, as evidenced by reduced membrane potential and ATP production. Proteomic analysis revealed mitochondrial protein alterations, and Ca-induced ROS accumulation promoted apoptosis. In vivo, Ca (100 mg/kg/day) effectively suppressed tumor growth without significant adverse effects. Notably, Ca’s effects were unique compared to other SGLT2 inhibitors, indicating mechanisms independent of SGLT2 inhibition.
Conclusion: Ca inhibits Tsc2−/− cell proliferation through dual mechanisms of cell cycle arrest and mitochondrial impairment, demonstrating significant therapeutic potential for TSC-related lesions. These findings highlight Ca as a promising alternative to current mTOR inhibitors, warranting further investigation into its molecular targets and clinical applications.
Keywords: canagliflozin, rare diseases, mitochondrial impairment, Tsc2 gene